GT201700245A - Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina - Google Patents

Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina

Info

Publication number
GT201700245A
GT201700245A GT201700245A GT201700245A GT201700245A GT 201700245 A GT201700245 A GT 201700245A GT 201700245 A GT201700245 A GT 201700245A GT 201700245 A GT201700245 A GT 201700245A GT 201700245 A GT201700245 A GT 201700245A
Authority
GT
Guatemala
Prior art keywords
ketamine
csa
salt
processes
preparation
Prior art date
Application number
GT201700245A
Other languages
English (en)
Inventor
Yi Chen Cheng
Oliver-Floegel
Justus Michael
Maurer Adrian
Reuter Karl
Wedel Tobias
STRITTMATTER Tobias
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of GT201700245A publication Critical patent/GT201700245A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/23Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/19Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/36Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA A PROCESOS PARA LA PREPARACIÓN DE ESKETAMINA. LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA, ADEMÁS A PROCESOS PARA LA RESOLUCIÓN DE S-KETAMINA A PARTIR DE UNA MEZCLA RACÉMICA O ENANTIOMÉRICAMENTE ENRIQUECIDA DE KETAMINA. LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA, ADEMÁS, A UNA SAL DE (S)-CSA DE S-KETAMINA, MÁS PARTICULARMENTE, UNA FORMA MONOHIDRATO DE LA SAL DE (S)-CSA DE S-KETAMINA; Y A UNA SAL DE (R)-CSA DE R-KETAMINA.
GT201700245A 2015-05-13 2017-11-13 Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina GT201700245A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562160659P 2015-05-13 2015-05-13

Publications (1)

Publication Number Publication Date
GT201700245A true GT201700245A (es) 2019-08-07

Family

ID=56068863

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201700245A GT201700245A (es) 2015-05-13 2017-11-13 Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina

Country Status (25)

Country Link
US (3) US20160332962A1 (es)
EP (1) EP3294704B1 (es)
JP (1) JP6882990B2 (es)
KR (1) KR102610047B1 (es)
CN (1) CN107750245B (es)
AU (1) AU2016260911B2 (es)
BR (1) BR112017024243B1 (es)
CA (1) CA2985696A1 (es)
CL (3) CL2017002854A1 (es)
CO (1) CO2017011553A2 (es)
CR (1) CR20170517A (es)
EA (1) EA201792503A1 (es)
EC (1) ECSP17075386A (es)
ES (1) ES2767708T3 (es)
GT (1) GT201700245A (es)
HK (1) HK1251546A1 (es)
IL (1) IL255433B2 (es)
MX (1) MX2017014473A (es)
MY (1) MY181938A (es)
PE (1) PE20180527A1 (es)
PH (1) PH12017502024A1 (es)
SA (1) SA517390322B1 (es)
UA (1) UA121049C2 (es)
WO (1) WO2016180984A1 (es)
ZA (1) ZA201708417B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
MX2017001908A (es) 2014-08-13 2017-08-08 Janssen Pharmaceutica Nv Metodo para el tratamiento de la depresion.
CA2961208A1 (en) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
CN117531017A (zh) 2017-12-22 2024-02-09 詹森药业有限公司 用于治疗抑郁症的艾司氯胺酮
ES2907692T3 (es) * 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
BR112020016500A2 (pt) 2018-02-15 2020-12-15 National University Corporation Chiba University Agente preventivo ou terapêutico e composição farmacêutica para doença inflamatória ou doença óssea
CN110218157B (zh) * 2018-03-01 2022-08-23 江苏恒瑞医药股份有限公司 一种r-氯胺酮及其可药用盐的制备方法
AU2019262197A1 (en) 2018-05-04 2020-11-26 Perception Neuroscience, Inc. Methods of treating substance abuse
KR20210028159A (ko) * 2018-06-27 2021-03-11 클렉시오 바이오사이언시스 리미티드 주요 우울 장애를 치료하는 방법
CN108659004B (zh) * 2018-07-12 2020-11-10 福安药业集团重庆博圣制药有限公司 奥拉西坦异构体的制备方法
AU2019352028A1 (en) 2018-10-05 2021-03-11 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
MA55218A (fr) 2019-03-05 2022-01-12 Janssen Pharmaceuticals Inc Eskétamine pour le traitement de la dépression
US20220220062A1 (en) * 2019-04-16 2022-07-14 Janssen Pharmaceutica Nv Synthetic methods of preparing esketamine
CN112375005A (zh) * 2019-08-16 2021-02-19 国药集团工业有限公司 一种氯胺酮、其衍生物或其盐的消旋化方法
EP4084786A1 (en) 2019-12-30 2022-11-09 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
WO2022208144A1 (en) * 2021-03-31 2022-10-06 Supriya Lifescience Ltd A crystalline form of 2-(2-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride and method thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) * 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS5857420B2 (ja) * 1975-02-12 1983-12-20 ワコウジユンヤクコウギヨウ カブシキガイシヤ Dl− フエニルグリシンノ コウガクブンカツホウホウ
JPS632932A (ja) 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
JPS6314771A (ja) * 1986-07-08 1988-01-21 Sankyo Co Ltd 光学活性イミダゾ−ル誘導体およびその製法
JPS63192753A (ja) * 1987-02-05 1988-08-10 Otsuka Pharmaceut Co Ltd テトラヒドロキノリン誘導体の光学分割法
DE4312016A1 (de) 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
JPH10507192A (ja) 1994-10-17 1998-07-14 アクゾ ノーベル ナムローゼ フェンノートシャップ ラセミ混合物から鏡像異性体を分離する方法
PE8798A1 (es) 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
DE19619665C2 (de) * 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
TW430660B (en) * 1996-05-30 2001-04-21 Mochida Pharm Co Ltd Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them
EP1113785B1 (en) 1998-07-24 2005-04-13 Seo Hong Yoo Clear aqueous solutions of bile acids
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
EP1103256A1 (de) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
BRPI0002693B8 (pt) * 2000-06-19 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis
US7973043B2 (en) 2002-07-30 2011-07-05 Peter Migaly Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
EP2012762A4 (en) 2006-03-22 2010-03-10 Sinai School Medicine INTRANASAL ADMINISTRATION OF KETAMINE FOR THE TREATMENT OF DEPRESSION
WO2007122130A1 (en) * 2006-04-21 2007-11-01 Zach System S.P.A. Process for preparing dorzolamide
EP2029136A4 (en) 2006-05-22 2010-01-06 Vanda Pharmaceuticals Inc TREATMENT FOR DEPRESSION DISEASES
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US8710070B2 (en) * 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
DK2582366T3 (en) 2010-06-15 2015-12-07 Gruenenthal Gmbh A pharmaceutical combination for the treatment of pain.
MX354547B (es) 2011-11-14 2018-03-09 Alfasigma Spa Ensayos y métodos para seleccionar un regimen de tratamiento para un sujeto con depresión.
US9012486B2 (en) * 2011-11-14 2015-04-21 Alex Chervinsky Topical composition for pain relief
PE20141906A1 (es) 2012-03-12 2014-12-05 Janssen Pharmaceutica Nv Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
US20140057988A1 (en) 2012-08-23 2014-02-27 Stuart WEG Anxiolytic composition, formulation and method of use
AU2013328280B2 (en) 2012-10-08 2017-12-21 Auckland Uniservices Limited Ketamine derivatives
EP4309735A3 (en) 2013-03-15 2024-04-17 JANSSEN Pharmaceutica NV Pharmaceutical composition of s-ketamine hydrochloride
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
JP6462663B2 (ja) 2013-04-12 2019-01-30 アイカーン スクール オブ メディシン アット マウント シナイ 心的外傷後ストレス障害を処置するための方法
DK3043785T3 (da) * 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression

Also Published As

Publication number Publication date
ECSP17075386A (es) 2018-02-28
BR112017024243B1 (pt) 2021-12-07
ES2767708T3 (es) 2020-06-18
KR102610047B1 (ko) 2023-12-05
EP3294704B1 (en) 2019-10-30
MX2017014473A (es) 2018-03-21
US10815196B2 (en) 2020-10-27
US20180282266A1 (en) 2018-10-04
US20160332962A1 (en) 2016-11-17
ZA201708417B (en) 2018-11-28
JP2018516891A (ja) 2018-06-28
CA2985696A1 (en) 2016-11-17
CL2020001852A1 (es) 2020-10-23
IL255433B2 (en) 2023-07-01
IL255433B1 (en) 2023-03-01
HK1251546A1 (zh) 2019-02-01
BR112017024243A2 (pt) 2018-07-17
AU2016260911A1 (en) 2017-11-16
CL2017002854A1 (es) 2018-04-20
CR20170517A (es) 2017-12-05
EP3294704A1 (en) 2018-03-21
CN107750245A (zh) 2018-03-02
CL2019001066A1 (es) 2019-06-21
SA517390322B1 (ar) 2023-07-16
CN107750245B (zh) 2021-06-22
UA121049C2 (uk) 2020-03-25
PH12017502024A1 (en) 2018-04-02
WO2016180984A1 (en) 2016-11-17
MY181938A (en) 2021-01-14
JP6882990B2 (ja) 2021-06-02
US20210024461A1 (en) 2021-01-28
AU2016260911B2 (en) 2020-02-27
IL255433A (en) 2018-02-28
KR20180008568A (ko) 2018-01-24
EA201792503A1 (ru) 2018-02-28
CO2017011553A2 (es) 2018-04-19
PE20180527A1 (es) 2018-03-19

Similar Documents

Publication Publication Date Title
GT201700245A (es) Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
TWD181857S (zh) 香水瓶
CO2017001884A2 (es) Polimorfos de selinexor
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201692105A1 (ru) Новые пиразолопиримидиновые производные и их применение в качестве ингибиторов malt1
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
MX2017008136A (es) Sal de l-tartrato de pridopidina.
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
BR112015028853A2 (pt) Composição detergente com ph baixo
DOP2016000253A (es) Nuevos compuestos
BR112017000135B8 (pt) Processo para a preparação de ácidos 4-alcóxi-3-hidroxipicolínico
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
EA201591678A1 (ru) Антиперспирантные композиции
AR100365A1 (es) Composición acuosa que comprende ibuprofeno y paracetamol en combinación, proceso para fabricarla y dispositivo inyector para administrarla
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
EA201791645A1 (ru) Новые соли и полиморфы scy-078
CL2018002149A1 (es) Proceso.
DE102016003950A8 (de) Maschinenstrang zur Herstellung von Salpetersäure
BR112016023767A2 (pt) forma sólida, composição farmacêutica, compostos, métodos, composições e utilizações
BR112015028751A2 (pt) processo para a preparação de derivados de 3,5-bis (fluoralquil)pirazol a partir de alfa,alfa-dihaloaminas
MX2017003498A (es) Sal de ester metilico de fenilglicina.
MX2017004770A (es) Formas solidas del clorhidrato de nilotinib.
BR112017016626A2 (pt) micro-organismo com capacidade para produzir ácido quinólico e método para produzir ácido quinólico com o uso do micro-organismo